Contact
searchSearch
HMP Global
Login

Glioma News

News
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
04/29/2026
Emily Estrada
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study...
04/29/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
News
Pharmacist-Led Interventions Improve Medication Management for Patients Receiving Vorasidenib for Low-Grade Gliomas
03/24/2026
Stephanie Holland
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective,...
03/24/2026
Oncology
News
Auceliciclib Demonstrates Favorable Safety and Preliminary Activity in Advanced Solid Tumors and Recurrent High-Grade Glioma
03/03/2026
Emily Estrada
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated...
03/03/2026
Oncology
News
¹⁸F-DOPA-PET Detects Early Treatment Response in IDH-Mutant Glioma
02/06/2026
Stephanie Holland
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world...
02/06/2026
Radiopharmaceutical Education Institute
News
Survival Outcomes of Immune Checkpoint and mTOR Inhibitor Therapies for Patients With Glioblastoma
01/26/2026
Gina Tomaine
Neither immune checkpoint nor mTOR inhibitors consistently improved survival in unselected glioblastoma populations. However, tailored approaches based on molecular features or delivery methods may offer benefits, according to a recent...
Neither immune checkpoint nor mTOR inhibitors consistently improved survival in unselected glioblastoma populations. However, tailored approaches based on molecular features or delivery methods may offer benefits, according to a recent...
Neither immune checkpoint nor...
01/26/2026
Oncology
News
Eflornithine Plus Lomustine vs Lomustine Monotherapy for Recurrent Grade 3 Astrocytoma: Phase 3 STELLAR Trial
01/13/2026
Gina Tomaine
Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy.
Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy.
Results showed that eflornithine...
01/13/2026
Oncology
News
Safusidenib Erbumine Shows Promise in Newly Diagnosed IDH1-Mutated Grade 2 Gliomas
12/05/2025
Stephanie Holland
According to results from a phase 2 study, safusidenib erbumine demonstrates promising clinical efficacy and safety among newly diagnosed patients with grade 2 IDH1-mutated gliomas.
According to results from a phase 2 study, safusidenib erbumine demonstrates promising clinical efficacy and safety among newly diagnosed patients with grade 2 IDH1-mutated gliomas.
According to results from a...
12/05/2025
Oncology
News
Vorasidenib Added to Temozolomide Shows Favorable Safety in IDH1/2-Mutated Gliomas
12/05/2025
Stephanie Holland
Findings from a phase 1b trial show the addition of 40 mg of once daily vorasidenib to standard temozolomide demonstrates acceptable safety in IDH 1/2-mutated gliomas.
Findings from a phase 1b trial show the addition of 40 mg of once daily vorasidenib to standard temozolomide demonstrates acceptable safety in IDH 1/2-mutated gliomas.
Findings from a phase 1b trial...
12/05/2025
Oncology
News
Vorasidenib Sustains Clinical Benefit in IDH1/2-Mutant Glioma: Longer-Term Results From the INDIGO Trial
11/12/2025
Stephanie Holland
Longer-term results from the ongoing phase 3 INDIGO trial show vorasidenib continues to demonstrate clinical benefit and reductions in tumor volume and seizure frequency among patients with grade 2 IDH1/2-mutant diffuse glioma.
Longer-term results from the ongoing phase 3 INDIGO trial show vorasidenib continues to demonstrate clinical benefit and reductions in tumor volume and seizure frequency among patients with grade 2 IDH1/2-mutant diffuse glioma.
Longer-term results from the...
11/12/2025
Oncology

Recent News

FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
FDA Approval
FDA Approves Vepdegestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
05/01/2026
Emily Estrada
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase...
05/01/2026
Oncology
News
Varegacestat Advances Toward FDA Review in Desmoid Tumors
04/30/2026
Stephanie Holland
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase...
04/30/2026
Oncology
News
Nirogacestat Improves Outcomes Across Prognostic Subgroups of Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis...
04/30/2026
Oncology
News
FOG-001 Shows Early Activity in Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study...
04/30/2026
Oncology
News
Bireociclib Plus Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer
04/30/2026
Emily Estrada
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3...
04/30/2026
Oncology
News
Romiplostim Reduces the Need for Dose Modifications in Chemotherapy-Induced Thrombocytopenia
04/30/2026
Emily Estrada
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE...
04/30/2026
Oncology
News
Tri-Weekly Cisplatin Matches Weekly Dosing With Better Tolerability in Cervical Cancer
04/30/2026
Stephanie Holland
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO...
04/30/2026
Oncology
FDA Alerts
FDA Grants Breakthrough Therapy Designation to TERN-701 in Ph-Positive Chronic Myeloid Leukemia
04/30/2026
Stephanie Holland
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2...
04/30/2026
Oncology
News
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
04/29/2026
Emily Estrada
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study...
04/29/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use